Disease · MONDO_0002691
liver cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. liver cancer. Diseases, record MONDO_0002691. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002691
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of liver, hepatic cancer, malignant liver neoplasm, malignant neoplasm of liver, malignant neoplasm of liver, not specified as primary or secondary, malignant neoplasm of liver, primary, malignant tumour of liver, primary liver cancer, primary malignant liver neoplasm, primary malignant neoplasm of liver
- Open Targets
Drugs109
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| YTTRIUM Y-90 | CHEMBL4650364 | Small molecule | Approval | TTD | 3 | 2 | 2 | Drugs and targets |
| CARMUSTINE | CHEMBL513 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| FERUMOXIDES | CHEMBL1201502 | Approval | TTD | 1 | 0 | 0 | Drugs and targets | |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| SORAFENIB TOSYLATE | CHEMBL1200485 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| LENVATINIB | CHEMBL1289601 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
1 to 10 of 109
See all 109 drugsTargets153
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 7 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 5 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| TYMS | Thymidylate synthase | 5 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 4 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 4 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
1 to 10 of 153
See all 153 targetsTrials102
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection | Phase 3 | 520 | 2020-12-30 | Cancer, Liver Cancer, Hepatocellular Carcinoma | MUPARFOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01015833 | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Phase 3 | 356 | 2018-05-02 | Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma | DOXORUBICIN HYDROCHLORIDE, SORAFENIB TOSYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | Phase 1 | 252 | 2025-11-10 | Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms | EZABENLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Phase 3 | 235 | 2023-02-17 | Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | CISPLATIN, DOXORUBICIN, MITOMYCIN, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT03733990 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Phase 1/2 | 216 | 2025-04-02 | Cancer | BEXMARILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03092895 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | Phase 2 | 157 | 2026-01-29 | Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma | CAMRELIZUMAB, FLUOROURACIL, GEMCITABINE, LEUCOVORIN, OXALIPLATIN, RIVOCERANIB | Its record names the disease | ClinicalTrials.gov |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | Phase 1/2 | 111 | 2024-08-13 | Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00881751 | Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | Phase 2 | 95 | 2017-09-11 | Liver Cancer | BEVACIZUMAB, ERLOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00183885 | A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma | Phase 2 | 76 | 2025-10-30 | Hepatocellular Carcinoma, Liver Cancer | CISPLATIN, MITOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT00605722 | A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. | Phase 2 | 51 | 2014-07-14 | Liver Cancer | BEVACIZUMAB, ERLOTINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 102
See all 102 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PI-88 vs Placebo: serious adverse events | 30 of 258 | 15 of 260 | 518 | NCT01402908 | Trial comparisons |
| Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) vs Arm II (Sorafenib Tosylate): deaths from any cause | 12 of 167 | 16 of 171 | 338 | NCT01015833 | Trial comparisons |
| Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) vs Arm II (Sorafenib Tosylate): serious adverse events | 71 of 167 | 57 of 171 | 338 | NCT01015833 | Trial comparisons |
| Arm A (Sorafenib and TACE) vs Arm B (Placebo and TACE): deaths from any cause | 85 of 118 | 88 of 117 | 235 | NCT01004978 | Trial comparisons |
| Arm A (Sorafenib and TACE) vs Arm B (Placebo and TACE): serious adverse events | 65 of 110 | 41 of 108 | 218 | NCT01004978 | Trial comparisons |
| Arm I vs Arm II: serious adverse events | 25 of 47 | 19 of 43 | 90 | NCT00881751 | Trial comparisons |
| Arm A: 5 Days/Week Schedule vs Arm B: 3 Days/Week Schedule: Number of Participants With Adverse Events | 23 of 23 | 23 of 23 | 46 | NCT01171924 | Trial comparisons |
| Arm A: 5 Days/Week vs Arm B: 3 Days/Week: serious adverse events | 12 of 23 | 9 of 23 | 46 | NCT01171924 | Trial comparisons |
Papers from its trials48
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002691
GET https://conductscience.org/api/diseases/v1/MONDO_0002691/drugs?page=2